Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297382 | 0.84 | MMP13 (0.58) | MMP13MAPK10 | |
| SCHEMBL5697256 | 0.82 | MMP13 (0.78) | MMP13P2RX3NAMPT | |
| SCHEMBL2316656 | 0.80 | SCD (0.66) | MMP13 | |
| SCHEMBL5696971 | 0.80 | MMP13 (0.65) | MMP13 | |
| SCHEMBL4550040 | 0.79 | HDAC6 (0.49) | MMP13P2RX3MAPK10USP2NAMPT | |
| SCHEMBL23520500 | 0.76 | MMP13 (0.65) | MMP13 | |
| SCHEMBL5696866 | 0.76 | MMP13 (0.56) | MMP13 | |
| SCHEMBL6298035 | 0.75 | MMP13 (0.64) | MMP13MEN1KMT2A | |
| SCHEMBL268837 | 0.74 | NPSR1 (0.55) | MMP13USP2KMT2APOLBMAPT | |
| SCHEMBL6834151 | 0.73 | MMP13 (1.00) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| US-6894057-B2 | Oxo-azabicyclic compounds | WARNER-LAMBERT COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6747147-B2 | INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER | WARNER-LAMBERT COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | MMP13 1/4885P2RX3 3134/4885MAPK10 4318/4885 |
| US-20030220355-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, CA13 | MMP13 1/4885P2RX3 3152/4885MAPK10 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.